AACR Cancer Experts Forecast Research and Treatment Advances for 2024
PHILADELPHIA – Cancer Research Catalyst, the official blog of the American Association for Cancer Research (AACR), is starting the new year with a four-part series in which eminent AACR experts will forecast cancer research and treatment advances in 2024.
The first post in this series was published today and features Catherine J. Wu, MD, FAACR, the Lavine Family Chair of Preventative Cancer Therapies at Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School, discussing progress and promise in the field of cancer vaccines. Read the post.
Stay tuned for parts 2-4 in the coming weeks, which will feature predictions from:
- Robert A. Winn, MD, FAACR, VCU Massey Comprehensive Cancer Center, on achieving health equity;
- Paul Workman, FMedSci, The Institute of Cancer Research in London, on using AI and other cutting-edge technologies for oncology drug discovery; and
- AACR President-Elect Patricia M. LoRusso, DO, PhD (hc), FAACR, Yale Cancer Center and Smilow Cancer Hospital, on precision medicine and biomarker-driven clinical trials.
Journalists are welcome to use any content from the series, including graphics. Please cite the American Association for Cancer Research and link to the posts.
This series is part of the continuing mission of Cancer Research Catalyst to further accelerate the growth and spread of knowledge about cancer while providing helpful and interesting information to AACR members and the public.